{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:26:43Z","timestamp":1761514003858,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,5,9]],"date-time":"2017-05-09T00:00:00Z","timestamp":1494288000000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"60P"},{"name":"60P"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Travel Medicine and Infectious Disease"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.tmaid.2017.05.006","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T22:19:12Z","timestamp":1494281952000},"page":"28-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Tafenoquine is not neurotoxic following supertherapeutic dosing in rats"],"prefix":"10.1016","volume":"17","author":[{"given":"Geoffrey S.","family":"Dow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Reid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Toovey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2013","series-title":"Medicines for Malaria Venture. Breakthrough Therapy designation for potential new anti-relapse medicine for malaria","key":"10.1016\/j.tmaid.2017.05.006_bib1"},{"issue":"2","key":"10.1016\/j.tmaid.2017.05.006_bib2","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.00354-09","article-title":"Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects","volume":"54","author":"Nasveld","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.tmaid.2017.05.006_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.tmaid.2008.12.004","article-title":"Mefloquine neurotoxicity: a literature review","volume":"7","author":"Toovey","year":"2009","journal-title":"Travel Med Infect Dis"},{"issue":"2","key":"10.1016\/j.tmaid.2017.05.006_bib4","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.tmaid.2015.03.010","article-title":"Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe","volume":"13","author":"Schlagenhauf","year":"2015","journal-title":"Travel Med Infect Dis"},{"issue":"3","key":"10.1016\/j.tmaid.2017.05.006_bib5","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1128\/AAC.50.3.1045-1053.2006","article-title":"Mefloquine induces dose-related neurological effects in a rat model","volume":"50","author":"Dow","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"year":"2000","series-title":"International Conference on Harmonization. Safety pharmacology studies for human pharmaceuticals, Safety Pharmacology Studies for Human Pharmaceuticals S7A","key":"10.1016\/j.tmaid.2017.05.006_bib6"},{"issue":"1","key":"10.1016\/j.tmaid.2017.05.006_bib7","first-page":"85","article-title":"Screening approaches to neurotoxicity: a functional observational battery","volume":"8","author":"Moser","year":"1989","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.tmaid.2017.05.006_bib8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/01926230600713269","article-title":"\u201cbest practices\u201d approach to neuropathologic assessment in developmental neurotoxicity testing\u2013for today","volume":"34","author":"Bolon","year":"2006","journal-title":"Toxicol Pathol"},{"issue":"12","key":"10.1016\/j.tmaid.2017.05.006_bib9","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1086\/324081","article-title":"A\u00a0new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria","volume":"33","author":"Shanks","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tmaid.2017.05.006_bib10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.trstmh.2008.04.024","article-title":"The efficacy and tolerability of three different regimens of tafenoquine versus primaquine for post-exposure prophylaxis of Plasmodium vivax malaria in the Southwest Pacific","volume":"102","author":"Elmes","year":"2008","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.tmaid.2017.05.006_bib11","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1128\/AAC.42.5.1293","article-title":"Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial","volume":"42","author":"Brueckner","year":"1998","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Travel Medicine and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893917300777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1477893917300777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:02:42Z","timestamp":1761487362000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1477893917300777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":11,"alternative-id":["S1477893917300777"],"URL":"https:\/\/doi.org\/10.1016\/j.tmaid.2017.05.006","relation":{},"ISSN":["1477-8939"],"issn-type":[{"type":"print","value":"1477-8939"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tafenoquine is not neurotoxic following supertherapeutic dosing in rats","name":"articletitle","label":"Article Title"},{"value":"Travel Medicine and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmaid.2017.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}